NCT05579236Active, not recruiting
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
An Observational Longitudinal Cohort Study to Investigate Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
The aim of this study is to find out whether a new image analysis technique called Cortical Disarray Measurement (CDM) could be used to help better diagnose Alzheimer's disease. This study will see whether changes on CDM can be used to identify Alzheimer's disease from a group of people living with memory and thinking problems. The study will also explore how CDM relates to changes in memory or thinking over time.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 16 Sept 2022
- Start date
- 28 Sept 2022
- Primary completion date
- Sept 2026
- Lead sponsor
- University Hospital Southampton NHS Foundation Trust
- Diseases
- Alzheimer disease
- NCT number
- NCT05579236
What you commit to
- Study type: Observational
- Planned participants: 400
- From 28 Sept 2022 to the primary completion date, Sept 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- A condition or reason, in the investigator's judgement, that would question the validity of the acquired companion reported data
Other
- Do not meet the inclusion criteria
- No study companion available
- Individuals with a non-progressive learning disability
- Pregnant or intending to become pregnant during the study
- COMPANION PARTICIPANTS
- Individuals who are not fluent in English
Who the study is looking for
- Diagnosis of mild cognitive impairment (MCI) or prodromal Alzheimer's Disease (AD) as defined by National Institute on Ageing/Alzheimer's Association (NIA/AA) diagnostic criteria for MCI/prodromal AD, NOT including MCI unlikely due to AD; OR, Diagnosis of Alzheimer's disease as defined by NIA/AA criteria for probable AD
- Clinical dementia rating (CDR) scale global score of very mild or mild (0.5 or 1) impairment
- Ability to undergo and tolerate MRI scans, with no contraindications to MRI
- Ability to tolerate blood draws
- Ability to give informed consent to participate in the study
- Aged over 18 years
- Sufficient knowledge on study participant's condition to complete companion assessments of the patient, in the investigator's judgement
- Able and willing to attend all clinical visits for completion of companion assessments or provide the relevant assessments remotely via phone or video call
Criteria the registry did not label
- PATIENT PARTICIPANTS
Age in the registry: 50 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dorset Healthcare University NHS Foundation Trust Coordinator of this site? Confirm its status | Bournemouth | United Kingdom | Unknown status |
| Cardiff and Vale University Health Board Coordinator of this site? Confirm its status | Cardiff | United Kingdom | Unknown status |
| University Hospital Southampton NHS Foundation Trust Coordinator of this site? Confirm its status | Southampton | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.